<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269241</url>
  </required_header>
  <id_info>
    <org_study_id>CF111/303</org_study_id>
    <nct_id>NCT02269241</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles</brief_title>
  <official_title>A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratories Leon Farma, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chemo France</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Insud Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and
      tolerability of LF111 and assessment of pharmacokinetics of LF111.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a prospective, multicenter, open-label, non-controlled trial in female
      subjects, including adolescents between the ages of 15+(inclusive) who present to the clinic
      seeking contraception, who are postmenarcheal and premenopausal.

      At screening, informed consent will be obtained and the screening procedures will be
      performed. After confirmation of the subject's eligibility, the subject will be provided with
      the investigational product and trained in the use of an electronic diary. Afterwards, the
      subjects will attend visit the clinical site on Day 20±2 of the 1st, 3rd, 6th and 9th cycles
      and on Day 29+2 of the 13th cycle. The last clinical site visit will occur 10-14 days after
      the 13th cycle visit.

      The trial will include women who have never used hormonal contraceptives before consent
      (naïve users), women who have not used hormonal contraceptives in the past three months
      before consent or who have used hormonal contraceptives in the past but have a
      contraceptive-free time of less than three months before consent (previous users) as well as
      women directly switching from another hormonal method (switchers). Women who have used
      hormonal contraceptives in the past but have a contraceptive-free time of less than three
      months before consent are allowed to be included into the trial if they had at least one
      complete menstrual cycle before enrollment.

      A population pharmacokinetic (PK) analysis planned in the whole subject population, will
      obtain sparse blood samples to determine plasma concentrations. In total, four blood samples
      will be collected: two samples each will be collected during the 1st cycle and during the 6th
      cycle of treatment.

      Adverse events and safety information will be collected throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2014</start_date>
  <completion_date type="Actual">October 4, 2017</completion_date>
  <primary_completion_date type="Actual">October 4, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Pregnancies (Evaluable Cycles)</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Pearl index (PI) from Evaluable Cycles in non-breastfeeding women aged ≤ 35 years (at the time of trial enrollment).
The PI calculation was based on the following formula:
PI(evaluable cycles)= (∑ on-drug confirmed pregnancy ∈{exposure cycles})/(#{exposure cycles} ) X 1300</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Pregnancies (All)</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Pearl Index based on overall cycles (overall PI) in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Pregnancies (Method Failures)</measure>
    <time_frame>up to 13 months</time_frame>
    <description>PI for method failures in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Ratio</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Pregnancy ratio in women aged ≤ 35 years (at the time of trial enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall PI, PI for Method Failures</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Overall PI, PI for method failures, PI (using evaluable cycles) and pregnancy ratio (life table analysis) in all women and in women up to 13 months (confirmed pregnancies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety</measure>
    <time_frame>up to to 13 months</time_frame>
    <description>Adverse events and changes in vital signs, clinical laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability; Vaginal Bleeding Pattern</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Vaginal bleeding pattern</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Pregnancies (by BMI and Weight)</measure>
    <time_frame>up to 13 months</time_frame>
    <description>PI for evaluable cycles in women aged ≤ 35 years in total and by BMI and weight subgroups based on confirmed and on confirmed and suspected, non-confirmed pregnancies</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Pregnancies</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Overall PI based on confirmed and on confirmed and suspected, non-confirmed pregnancies in total and by BMI and weight subgroups</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1552</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>LF111 (drospirenone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single treatment arm receives LF111</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LF111 (drospirenone)</intervention_name>
    <description>One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.</description>
    <arm_group_label>LF111 (drospirenone)</arm_group_label>
    <other_name>CF111</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sexually active, postmenarcheal and premenopausal female subjects at risk of pregnancy
             including breastfeeding women with no upper age limit.

          2. Female subjects at risk of pregnancy, between the ages of 15 and 17 (inclusive)
             provided that

               -  Applicable national, state and local laws allow subjects in this age group to
                  consent/assent to receive contraceptive services, and

               -  All applicable laws and regulations regarding the informed consent/assent of the
                  subjects to participate in clinical trials are observed.

          3. Regular cycles during the last six months before consent/assent when not using
             hormonal contraception.

          4. At least three complete menstrual cycles after delivery (only applicable for women who
             were pregnant within the last six months and for non-breastfeeding women).
             Breastfeeding women can be included six weeks after delivery irrespective of menstrual
             cycles post-delivery.

          5. At screening, maximum systolic blood pressure (median value of three values) ≤ 159 mm
             Hg and diastolic blood pressure (median value of three values) ≤ 99 mm Hg.

          6. Be able and willing to provide written informed consent or assent if the subject is
             adolescent, prior to undergoing any trial-related procedure.

          7. Willing to use trial contraception for thirteen 28-day cycles.

          8. Be willing to have intercourse each cycle of trial without the need to use back-up
             contraceptive.

          9. Be willing to state that, to her best knowledge, her male sexual partner(s):

               -  Has not had a vasectomy or been previously diagnosed as infertile.

               -  Has not been previously diagnosed or suspected of human immunodeficiency virus
                  (HIV) unless he has subsequently had a negative HIV test.

               -  Has not been known to have engaged in homosexual intercourse in the past five
                  years unless he has had negative HIV test results since then.

               -  Has not shared injection drug needles in the past unless he has had a negative
                  HIV test at least six weeks since last use.

         10. Agree not to participate in any other clinical trials during the course of this trial.

        Exclusion Criteria:

          1. Pregnant.

          2. Subject is known to or suspected of not being able to comply with the trial protocol,
             the use of the trial medication or the use of the trial diary.

          3. History of infertility.

          4. Abnormal finding on pelvic, breast or ultrasound examination that in the
             investigator's opinion contraindicates participation in the trial.

          5. Unexplained amenorrhea.

          6. Known polycystic ovary syndrome.

          7. Women ≥21 years of age with a Papanicolaou (pap) smear reading LGSIL or higher at
             screening (or six months prior to screening date). Human papilloma virus (HPV) testing
             in subjects with atypical squamous cells of undetermined significance (ASC-US) can be
             used as an adjunctive test.

               -  Subjects with ASC-US can be included if they are negative for high-risk HPV
                  strains.

               -  Subjects &lt;21 years of age do not require a pap smear.

          8. Known contraindication or hypersensitivity to ingredients or excipients of the IMP
             (Investigational Medicinal Product), including:

               1. Renal insufficiency

               2. Hepatic dysfunction

               3. Adrenal insufficiency

               4. Current or history of venous thrombophlebitis or thromboembolic disorders (venous
                  thromboembolism, which includes deep vein thrombosis and pulmonary embolism)

               5. Current or history of cerebral-vascular or coronary-artery disease

               6. Valvular heart disease with thrombogenic complications

               7. Diabetes with vascular involvement

               8. Headaches with focal neurological symptoms

               9. Major surgery with prolonged immobilization

              10. Known or suspected carcinoma of the breast

              11. Known or suspected sex-steroid sensitive malignancies

              12. Undiagnosed abnormal genital bleeding

              13. Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive
                  use

              14. Liver tumor (benign or malignant) or active clinically significant liver disease.

          9. Uncontrolled thyroid disorder (i.e., on stable dose of thyroid replacement for less
             than two months).

         10. Uncontrolled concomitant diseases (i.e., not on a stable treatment dose for at least
             two months).

         11. Evidence or history of alcohol, medication or drug abuse (within the last 12 months
             prior to consent/assent).

         12. Known inherited or acquired predisposition to venous thromboembolism or arterial
             thromboembolism (e.g., factor V Leiden, Prothrombin mutation, Antiphospholipid
             antibodies) or bruising within the last 12 months prior to consent/assent.

         13. Known or suspected HIV and/or hepatitis infection at screening.

         14. Received a dose of depot medroxyprogesterone acetate (DMPA or Depo-Provera®) during
             the 10 months prior to consent/assent, or received any combined injectable
             contraceptive (e.g., Cyclofem®) during the six months prior to consent/assent, or no
             spontaneous menses since last injection.

         15. Long-term treatment (longer than seven consecutive days within a month prior to V1b)
             of any medication that might interfere with the efficacy of hormonal contraceptives.

             Prohibited medication include:

               1. Anticonvulsants (e.g. phenytoin, carbamazepine, oxcarbazepine, topiramate,
                  felbamate, primidone)

               2. Barbiturates

               3. Rifampin

               4. Bosentan

               5. Griseofulvin

               6. St. John's wort (hypericum perforatum)

         16. Administration of human chorionic gonadotropin (hCG) or intake of co-medication
             containing hCG within a month prior to V1b).

         17. Progestin-releasing intra-uterine device (IUD) or contraceptive implant received or in
             place within the last two months prior to consent/assent.

         18. Planned regular concomitant use of barrier contraceptive methods, spermicides, IUDs or
             other contraceptive measures (excepting occasional use for safety reasons, e.g., to
             reduce risk of infection).

         19. Evidence or history of clinically significant psychiatric illness or suicide risk.

         20. Participation in another trial of an investigational drug or device parallel to the
             current trial or less than 90 days before consent/assent, or previous participation in
             the current trial and dispensed trial medication.

         21. Subject is a member of the investigator's or Sponsor's staff or a relative or family
             member thereof.

         22. Any condition that, in the opinion of the investigator, may jeopardize protocol
             compliance or the scientific integrity of the trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrico Colli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Exeltis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Care Research Corp.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center, LLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stamford Therapeutics Consortium</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - St. Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fellows Research Alliance, Inc.</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosemark WomenCare Specialists</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research, Inc</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence OBGYN Clinical Research, LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Women's Health &amp; Wellness, LLC</name>
      <address>
        <city>Plainsboro</city>
        <state>New Jersey</state>
        <zip>08536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Clinical Research</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Carolina Women's Center</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawthorne Medical Research, Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Obstetricians-Gynecology, Inc./Radiant Research, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fellows Research Alliance, Inc.</name>
      <address>
        <city>Bluffton</city>
        <state>South Carolina</state>
        <zip>29910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Associates</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Research Organization</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMC Life Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians' Research Options</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians' Research Options</name>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <zip>84062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Women's Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <results_first_submitted>June 14, 2019</results_first_submitted>
  <results_first_submitted_qc>July 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contraception</keyword>
  <keyword>hormonal oral contraceptive agents</keyword>
  <keyword>hormonal oral contraceptive</keyword>
  <keyword>oral contraceptive</keyword>
  <keyword>drospirenone</keyword>
  <keyword>LF111</keyword>
  <keyword>birth control</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drospirenone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 16, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02269241/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02269241/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Drospirenone 4 mg</title>
          <description>Single treatment arm receives LF111 film-coated tablets (24 white tablets containing 4.0 mg drospirenone, 4 green placebo tablets), oral administration once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1552"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1200"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Wish for pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Development of an exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>At the specific request of the sponsor</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Several reasons not classified</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screening failures</title>
              <participants_list>
                <participants group_id="P1" count="546"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1552 patients enrolled, 546 patients screening failures, 1006 patients analyzed, 352 patients completed</population>
      <group_list>
        <group group_id="B1">
          <title>LF111 (Drospirenone 4mg)</title>
          <description>Single treatment arm receives LF111 film-coated tablets (24 white tablets containing 4.0 mg drospirenone, 4 green placebo tablets), oral administration once daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1006"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1006"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="777"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="358"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="571"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Pregnancies (Evaluable Cycles)</title>
        <description>Pearl index (PI) from Evaluable Cycles in non-breastfeeding women aged ≤ 35 years (at the time of trial enrollment).
The PI calculation was based on the following formula:
PI(evaluable cycles)= (∑ on-drug confirmed pregnancy ∈{exposure cycles})/(#{exposure cycles} ) X 1300</description>
        <time_frame>up to 13 months</time_frame>
        <population>The population includes all non-breastfeeding subjects aged ≤ 35 years who were randomized, received at least one dose of study drug with sexual activity without using back-up contraception.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone 4 mg</title>
            <description>Single treatment arm receives LF111 film-coated tablets (24 white tablets containing 4.0 mg drospirenone, 4 green placebo tablets), oral administration once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pregnancies (Evaluable Cycles)</title>
          <description>Pearl index (PI) from Evaluable Cycles in non-breastfeeding women aged ≤ 35 years (at the time of trial enrollment).
The PI calculation was based on the following formula:
PI(evaluable cycles)= (∑ on-drug confirmed pregnancy ∈{exposure cycles})/(#{exposure cycles} ) X 1300</description>
          <population>The population includes all non-breastfeeding subjects aged ≤ 35 years who were randomized, received at least one dose of study drug with sexual activity without using back-up contraception.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="915"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.5" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Pregnancies (All)</title>
        <description>Pearl Index based on overall cycles (overall PI) in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)</description>
        <time_frame>up to 13 months</time_frame>
        <population>The population includes all non-breastfeeding subjects aged ≤ 35 years who were randomized and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LF111 (Drospirenone)</title>
            <description>single treatment arm receives LF111
LF111 (drospirenone): One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pregnancies (All)</title>
          <description>Pearl Index based on overall cycles (overall PI) in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)</description>
          <population>The population includes all non-breastfeeding subjects aged ≤ 35 years who were randomized and received at least one dose of study drug.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="915"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.4" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Pregnancies (Method Failures)</title>
        <description>PI for method failures in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)</description>
        <time_frame>up to 13 months</time_frame>
        <population>The population includes all non-breastfeeding subjects aged ≤ 35 years who were randomized, received at least one dose of study drug and used the IMP correctly.</population>
        <group_list>
          <group group_id="O1">
            <title>LF111 (Drospirenone)</title>
            <description>single treatment arm receives LF111
LF111 (drospirenone): One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pregnancies (Method Failures)</title>
          <description>PI for method failures in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)</description>
          <population>The population includes all non-breastfeeding subjects aged ≤ 35 years who were randomized, received at least one dose of study drug and used the IMP correctly.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="915"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.4" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Ratio</title>
        <description>Pregnancy ratio in women aged ≤ 35 years (at the time of trial enrollment)</description>
        <time_frame>up to 13 months</time_frame>
        <population>The population includes all subjects aged ≤ 35 years who were randomized, received at least one dose of study drug with evaluable cycles.</population>
        <group_list>
          <group group_id="O1">
            <title>LF111 (Drospirenone)</title>
            <description>single treatment arm receives LF111
LF111 (drospirenone): One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Ratio</title>
          <description>Pregnancy ratio in women aged ≤ 35 years (at the time of trial enrollment)</description>
          <population>The population includes all subjects aged ≤ 35 years who were randomized, received at least one dose of study drug with evaluable cycles.</population>
          <units>Cumulative Pregnancy Rate (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="915"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" lower_limit="0.87" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall PI, PI for Method Failures</title>
        <description>Overall PI, PI for method failures, PI (using evaluable cycles) and pregnancy ratio (life table analysis) in all women and in women up to 13 months (confirmed pregnancies)</description>
        <time_frame>up to 13 months</time_frame>
        <population>The population includes all ages subjects who were randomized and received at least one dose of study drug, non-breastfeeding women and used the IMP correctly.</population>
        <group_list>
          <group group_id="O1">
            <title>LF111 (Drospirenone)</title>
            <description>single treatment arm receives LF111
LF111 (drospirenone): One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall PI, PI for Method Failures</title>
          <description>Overall PI, PI for method failures, PI (using evaluable cycles) and pregnancy ratio (life table analysis) in all women and in women up to 13 months (confirmed pregnancies)</description>
          <population>The population includes all ages subjects who were randomized and received at least one dose of study drug, non-breastfeeding women and used the IMP correctly.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="993"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.2" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety</title>
        <description>Adverse events and changes in vital signs, clinical laboratory parameters</description>
        <time_frame>up to to 13 months</time_frame>
        <population>The population includes all subjects who received at least one dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>LF111 (Drospirenone)</title>
            <description>single treatment arm receives LF111
LF111 (drospirenone): One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety</title>
          <description>Adverse events and changes in vital signs, clinical laboratory parameters</description>
          <population>The population includes all subjects who received at least one dose of the IMP.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1006"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability; Vaginal Bleeding Pattern</title>
        <description>Vaginal bleeding pattern</description>
        <time_frame>up to 13 months</time_frame>
        <population>The population includes all subjects in full analysis set with bleeding.</population>
        <group_list>
          <group group_id="O1">
            <title>LF111 (Drospirenone)</title>
            <description>single treatment arm receives LF111
LF111 (drospirenone): One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability; Vaginal Bleeding Pattern</title>
          <description>Vaginal bleeding pattern</description>
          <population>The population includes all subjects in full analysis set with bleeding.</population>
          <units>Subjects with bleeding</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Pregnancies (by BMI and Weight)</title>
        <description>PI for evaluable cycles in women aged ≤ 35 years in total and by BMI and weight subgroups based on confirmed and on confirmed and suspected, non-confirmed pregnancies</description>
        <time_frame>up to 13 months</time_frame>
        <population>The population includes evaluable cycles in non-breastfeeding women aged ≤ 35 years , who were randomized and received at least one dose of study drug, including confirmed and suspected, non-confirmed pregnancies.</population>
        <group_list>
          <group group_id="O1">
            <title>LF111 (Drospirenone)</title>
            <description>single treatment arm receives LF111
LF111 (drospirenone): One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pregnancies (by BMI and Weight)</title>
          <description>PI for evaluable cycles in women aged ≤ 35 years in total and by BMI and weight subgroups based on confirmed and on confirmed and suspected, non-confirmed pregnancies</description>
          <population>The population includes evaluable cycles in non-breastfeeding women aged ≤ 35 years , who were randomized and received at least one dose of study drug, including confirmed and suspected, non-confirmed pregnancies.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="915"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pearl Index BMI&lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pearl Index BMI&gt;=30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0.8" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight &lt; Median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="2.4" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight &gt;= Median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overall Pregnancies</title>
        <description>Overall PI based on confirmed and on confirmed and suspected, non-confirmed pregnancies in total and by BMI and weight subgroups</description>
        <time_frame>up to 13 months</time_frame>
        <population>The population includes all ages subjects, non-breastfeeding women, who were randomized and received at least one dose of study drug, including confirmed and suspected, non-confirmed pregnancies.</population>
        <group_list>
          <group group_id="O1">
            <title>LF111 (Drospirenone)</title>
            <description>single treatment arm receives LF111
LF111 (drospirenone): One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Pregnancies</title>
          <description>Overall PI based on confirmed and on confirmed and suspected, non-confirmed pregnancies in total and by BMI and weight subgroups</description>
          <population>The population includes all ages subjects, non-breastfeeding women, who were randomized and received at least one dose of study drug, including confirmed and suspected, non-confirmed pregnancies.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="993"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pearl Index BMI&lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="1.7" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pearl Index BMI&gt;=30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.6" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight &lt; Median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="2.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight &gt;= Median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.6" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Drospirenone 4mg</title>
          <description>Single treatment arm receives LF111 film-coated tablets (24 white tablets containing 4.0 mg drospirenone, 4 green placebo tablets), oral administration once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>INDUCED LABOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1006"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1006"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Enrico Colli, Chief Scientific Officer</name_or_title>
      <organization>Exeltis</organization>
      <phone>+34917711500</phone>
      <email>enrico.colli@exeltis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

